CD274 and neoplasm: With the help of immune adjuvant R837, dendritic cells (DCs) can effectively process and present TAAs to activate effector T cells, meanwhile, a small-molecule PD-L1 inhibitor BMS-1 can block PD-1/PD-L1 pathway to reactivate cytotoxic T lymphocyte, resulting in a strong systemic antitumor immune response that is beneficial for limiting tumor metastasis.